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Background. Postpartum thyroiditis (PPT) is a common triphasic autoimmune disease in women with thyroid peroxidase (TPO)
autoantibodies. This study evaluated women’s thyroid disease symptoms, physical findings, stress levels, and thyroid stimulating
hormone (TSH) levels across six postpartum months in three groups, TPO negative, TPO positive, and PPT positive women.
Methods. Women were recruited in midpregnancy (𝑛 = 631) and TPO status was determined which then was used to form the
three postpartum groups. The three groups were compared on TSH levels, thyroid symptoms, weight, blood pressure, heart rate,
a thyroid exam, and stress scores. Results. Fifty-six percent of the TPO positive women developed PPT. Hypothyroid group (F (2,
742) = 5.8, 𝑃 = .003) and hyperthyroid group (F (2, 747) = 6.6, 𝑃 = .001) subscale scores differed by group. Several symptoms and
stress scores were highest in the PPT group. Conclusions. The normal postpartum is associated with many symptoms that mimic
thyroid disease symptoms, but severity is greater in women with either TPO or PPT positivity. While the most severe symptoms
were generally seen in PPT positive women, even TPO positive women seem to have higher risk for these signs and symptoms.

1. Introduction
The postpartum is considered a vulnerable time for the
development or recurrence of some autoimmune diseases
(ADs), particularly those caused by excessive T helper 1 (Th1)
lymphocyte mediated processes (eg. rheumatoid arthritis
(RA)), multiple sclerosis (MS), and postpartum thyroiditis
(PPT). These ADs often ameliorate during pregnancy but
then exacerbate or occur for the first time in the postpartum
period [1]. This is thought to be due to the return of Th1
mediated immunity, which is suppressed in pregnancy [2].
The most common postpartum autoimmune disease (AD)
is postpartum thyroiditis (PPT), a thyroid dysfunction that
occurs within the first year after delivery or miscarriage [3].
PPT occurs during the early postpartum in approximately
half of women who have autoantibodies to the enzyme,
thyroid peroxidase, during the first trimester of pregnancy
[4]. Thyroid peroxidase is a microsomal enzyme that is
required in the synthesis of thyroid hormone, but many
women who have this autoantibody remain euthyroid. PPT
usually has a triphasic course, from euthyroidism, to a short
hyperthyroid phase (22%) followed by a longer period of

hypothyroidism (48%) and a recovery to euthyroidism [5].
Variants of this course occur. Recently it has been shown that
up to fifty percent of women with PPT remain hypothyroid
at one year [6]. There is significant risk for women with
PPT (up to 50%) to develop permanent thyroid disease
over time [3, 6]. The pathophysiology involves Th1 cells,
autoantibodies, and autoreactive T helper 2 (Th2) cells that
promote antithyroid autoantibody production. Cytotoxic T
cells and NK cells also participate in a direct destruction
of the gland [7]. TPO autoantibodies are able to bind to
thyrocytes and activate complement, which sets in motion
antibody dependent cytotoxic mechanisms which involve
further destruction of the thyrocytes.
Symptoms that women with PPT experience are thought
to be related to the phase of disease. PPT symptoms during the hyperthyroid phase are usually short-lived and in
the hypothyroid phase are particularly likely to be underdiagnosed, as many women consider their experiences as
“normal” postpartum symptoms. Routine TPO antibody
screening is not done in pregnancy and many TPO positive women have no or subclinical symptoms of thyroid
dysfunction, so risk for PPT cannot be predicted for
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the individual untested woman unless she has had a previous
episode of the disease.
We examined differences across the course of the postpartum in TPO positive women compared to a TPO negative
comparison group. A list of common symptoms of hypo- and
hyperthyroidism was constructed, and women reported on
the occurrence and severity of each symptom at 7 consecutive
postpartum assessments. The current report compares symptoms, TSH levels, other hormones, and physical findings in
three groups, TPO negative, TPO positive, and PPT positive
women across six postpartum months.

2. Method
Institutional Review Board (IRB) approval was achieved and
informed consent gathered at the initiation of the study.
Pregnant women (𝑛 = 631) were recruited at prenatal clinics.
Study participants were women first measured for the TPO
autoantibody after the first trimester and before 25 weeks of
gestation and identified as either TPO positive or negative at
that time. Exclusion criteria included the following: age less
than 18 or older than 45 years; known autoimmune disease;
previous thyroid disease; HIV positivity; use of medications
that affect immunity; chronic diseases, such as diabetes; serious mental illness, such as bipolar disorder, schizophrenia,
untreated depression, or unresolved perinatal bereavement;
body mass index (BMI) <20; history of hyperemesis; current
multiple gestation; current pregnancy product of in vitro
fertilization (IVF); fetal abnormalities; and being unable to
participate in a six-month postpartum followup. All TPO
positive (𝑛 = 63) women who were identified in pregnancy
were invited into the postpartum phase of the study, while a
sample of TPO negative women (𝑛 = 568) were selected by a
random number generator to participate as the comparison
group in the postpartum phase (𝑛 = 72). TPO status
was determined by ELISA (ORGENTEC, Mainz, Germany)
according to kit directions using standards and controls and
done in duplicate. The coefficient of variation was always less
than 5%. TPO antibody titer greater than 20 IUs was used as
the cutoff value for positivity. TSH levels were also measured
in all TPO positive women at the initial pregnancy blood
draw. Women were not informed of their TPO status until the
end of the study, or unless they experienced PPT and needed
referral.

3. Materials and Procedure
Women recruited into this study received a home visit by a
research nurse one week after giving birth and then monthly
for postpartum months 1 through 6. At each postpartum
home visit, participants received a targeted physical examination (thyroid gland palpation, blood pressure, heart rate, and
weight). Detailed data were gathered on breastfeeding and
smoking, alcohol consumption, and exercise. They also completed a thyroid disease symptom list. This list consisted of 19
items and participants rated occurrence of symptoms as not
present (0), mild (1), moderate (2), severe (3), or very severe
(4) (Table 1). The list was developed by the investigators based
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Table 1: Demographic characteristics by group.

Income
BMI
Breastfeeding
Smoking
Parity

TPO negative

TPO positive

9% < $4999
31% > $69,999
29.7
52%
8%
1.03

.6% < $4999
1.1% < $4999
38% > $69,999 38% > $69,999
32.1
28.3
70%
56%
1.6%
0%
1.00
1.00

PPT positive

on a review of literature on symptoms of thyroid disease, a
review of older clinical screening instruments which were
deemed too difficult to use in the home setting [8], and
consultation with an endocrinologist.
The Perceived Stress Scale (PSS) [9] was used to assess
levels of self-reported stress and was completed at each
postpartum visit. The 14-item version of the scale evaluates
perceptions of stress using a Likert scale ranging from 0
(never) to 4 (very often). The internal consistency reliability
has been reported to be .84 to .86 in young adults. Congruent
and criterion validity for the scale has been demonstrated to
be excellent, although predictive validity declines over time
[9].
A venipuncture was performed and 15 mLs of blood
were drawn into heparinized vacutainers. The blood was
transported to the laboratory within 2 hours. Blood samples were centrifuged at 1200 g for 25 minutes at 4∘ C and
plasma aliquoted into Eppendorf tubes and frozen at −80∘ C
until later analysis in batches. TSH (ALPCO, Salem, N.H.)
was always measured at each visit for the TPO positive
women, regardless of symptoms, and assayed according to
kit directions. TPO negative women with severity scores on
the thyroid screening list indicating occurrence of hyperor hypothyroid symptoms also had TSH levels measured.
PPT was assessed as possible when a TSH level of less
than 0.3 or more than 3.0 mIU/L occurred. This is the level
chosen for screening of thyroid disease in adults [10] and
during pregnancy [11]. Women meeting these criteria were
referred to their health care providers for further diagnosis
and treatment. They continued in the study after referral. The
research nurse who made the postpartum home visits and the
research participants were blinded to TPO status.
Statistical analysis was performed using SPSS v. 22. Data
were analyzed descriptively and examined for normality and
transformed if necessary. One way analysis of variance was
computed on symptom subscale scores and PSS scores by
group. Spearman correlations were used for correlations
between TSH levels and signs and symptoms. A 𝑃 value
of <.05 was considered significant for these tests. KruskalWallis analyses were performed on individual symptoms by
group with a pairwise comparison test for post-hoc analyses.
Bonferroni corrections were made for multiple comparisons
with a 𝑃 < .003 considered significant for these tests.
Reliabilities (𝛼) were calculated for the symptoms on the
thyroid checklist hyperthyroid symptoms and hypothyroid
symptoms subscales.
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4. Results

14
12
TSH (U/mL)

TPO positivity was found in 63 of the 631 (10%) participants
at the pregnancy measurement point. All but two of the TSH
titers on these TPO positive women were in the euthyroid
range when measured in the plasma samples collected in
pregnancy (mean 1.46 ± .21; range 0.16–4.6 mIU/mL). Of the
63 TPO positive women, 46 agreed to be in the postpartum
followup. The reasons for not participating in the postpartum
follow-up study included moving to a different location,
lack of interest in the study, and being lost to followup.
The demographics of the TPO positive women who did not
participate were not different than those who did participate.
Of these 46 TPO positive participants, 26 (56.2%) developed
PPT during the first six months of the postpartum. There were
4 TPO negative women who developed symptoms and signs
of thyroid disease, including out of range TSH levels. These
women were not included in the analysis as they could have
developed another thyroid disease such as Graves’ disease.
The research was described to participants as a study of
immunity and hormones. However, if a woman became PPT
positive, she was informed of this result and referrals were
made to her health care provider, so from that point on she
did know her status.
TSH levels were either below 0.3 mIU/mL or above
3.0 mIU/mL for a woman to be classified as having potential
PPT. Thirteen had elevated TSH (hypothyroid) and thirteen
had low TSH (hyperthyroid) at time of identification of possible PPT (Figure 1). While we attempted to assure followup
with health care providers and potential further diagnostic
testing for these women, we found that there is a common
lack of knowledge about PPT by primary care providers, and
few responded to our inquiries about follow-up diagnosis
and treatment. In addition, some women had low incomes
and no health care available for followup. For purposes of
the study we classified TPO positive women as having likely
developed PPT when a change (often dramatic) from normal
TSH levels to levels outside the normal range occurred at
one of the monthly visits and remained abnormal thereafter.
No PPT positive woman, even those few who underwent
medical referral and treatment, became euthyroid after being
classified as PPT positive during the six-month course of
the study. Only two PPT positive women were prescribed
levothyronine and they continued in the study until the sixth
month. Removing these women from the analysis had no
effect on the results.
There were no differences in ethnicity by TPO status
or PPT positivity status. Table 1 depicts sociodemographic
variables by group. None of the differences were statistically
significant.
The thyroid symptom list had both common hyperthyroid and hypothyroid symptoms which were grouped and
analyzed as symptom severity subscales. Table 2 shows symptoms categorized as being most associated with hypothyroidism or hyperthyroidism. The hyperthyroidism scale was
comprised of 9 items (maximum severity score = 36) and
the hypothyroidism scale had 10 items (maximum severity
score = 40). The Cronbach’s 𝛼 for the hyperthyroid symptom
subscale was .70 and for the hypothyroid subscale was .77.

10
8
6
4
2
0

0

1
2
3
4
5
6
Home visit at which PPT was first identified

7

Figure 1: TSH levels in plasma at the time at which TPO positive
women were first identified as PPT positive. Home visit 1 was at 1week postpartum and the following time intervals were from month
1 through 6.
Table 2: Thyroid symptom screening.
Lack of energy
Irritability
Nervousness
Sweating
Dry skin
Shaking hands
Depression
Heat intolerance
Dry hair
Puffy face
Hair falling out
Weight loss
Constipation
Aches and pains
Tingling or numbness
Cold intolerance
Poor memory
Lack of concentration
Palpitations

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3

4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4

bold items comprise the hypothyroid subscale; non bold items comprise the
hyperthyroid subscale.
0: no presence of symptom; 1: mild; 2: moderate; 3: severe; 4: very severe.

At time of first identification of PPT status, the mean score
on the hypothyroid subscale was 8.5 ± 7.3 (SD) and on the
hyperthyroid subscale was 5.4 ± 5.0 (SD). Comparisons of
scores in the period before a woman became PPT positive
showed a score of 6.75 ± 5.5 for the hypothyroid subscale
and 6.87 ± 5.78 for the hyperthyroid scale, and these were
not statistically significantly different from the values at
identification of PPT positivity. However, the mean TSH
of 1.52 ± .8 (SD) preceding the identification of PPT was
significantly different (𝑡 = −3.0, 𝑃 = .005) than the TSH at
identification of presence of PPT (3.95 ± 3.96 (SD)).
Figures 2(a) and 2(b) depict the means of the hypothyroid
and hyperthyroid subscale scores across the postpartum for
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Mean hypothyroid scale score

Mean hyperthyroid scale score
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PPT+
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2
1
0

PPT−

TPO−

(a)

PPT+

(b)

Figure 2: (a) Hypothyroid subscale scores by group. Error bars are standard errors of the mean. (b) Hyperthyroid subscale scores by group.
Error bars are standard errors of the mean.

each group. A one-way between groups analysis of variance
was conducted to explore the effect of group (TPO negative,
TPO positive without PPT, and PPT positive) on the mean
hypothyroid and hyperthyroid subscale scores. There was a
statistically significant difference at the 𝑃 = .003 level in
hypothyroid subscale scores [𝐹 (2, 742) = 5.8, 𝑃 = .003].
Post-hoc comparisons using the Tukey HSD test indicated
that the mean score for the hypothyroid subscale was significantly higher for the PPT positive group (8.29) compared to
the TP0 negative group (6.53), but not significantly different
than the TPO positive, PPT negative group (7.47). With
regard to the hyperthyroid subscale, there was a statistically
significant difference in scores at the 𝑃 = .001 level
[𝐹 (2, 747) = 6.6, 𝑃 = .001]. Post-hoc analysis found
that there were significant differences in the hyperthyroid
subscale scores comparing TPO negative women (4.39) with
both TPO positive PPT negative (5.43) and PPT positive
(5.65) groups.
All groups reported experiencing symptoms and there
were no dramatic differences by group in the frequency of
reporting any symptom experience (Table 3). Table 4 depicts
the frequency of women who reported that a symptom
was either “severe” or “very severe.” Correcting for multiple comparisons by using a Bonferroni correction (𝑃 <
.003), six symptom severities were significantly different by
group (lack of energy, shaking hands, heat intolerance, cold
intolerance, poor memory, and lack of concentration). All
significant symptom severities were higher in both TPO
positive and PPT positive groups compared to TPO negative
women.
Twelve TPO positive women had palpable thyroid glands
and 5 PPT positive women and two TPO positive, PPT
negative, women had visible goiters. The five goiters in PPT
positive women were associated with extremely low TSH
levels in three women and high levels in two women.
Mean PSS scores were significantly different by group
[𝐹 (2, 755) = 11.1, 𝑃 < .001]. Post-hoc analysis showed
that PPT positive women had higher mean scores across the
postpartum (22.5) compared to TPO negative women (19.3)
(𝑃 < .001). However, the difference between PPT positive and
TPO positive, PPT negative women (20.8) was not significant
(𝑃 = .15).

Table 3: Percent of women reporting any symptoms on thyroid
symptom checklist by TPO and PPT status.
Symptom

TPO negative TPO positive

Lack of energy
Irritability
Nervousness
Weight loss
Sweating
Shaking hands
Palpitations
Heat intolerance
Dry hair
Puffy face
Dry skin
Hair falling out
Constipation
Aches and pains
Tingling or
numbness
Cold intolerance
Poor memory
Lack of
concentration
Depression

TPO positive
PPT positive

68.4%
49.6%
32.7%
44.5%
31.5%
11.6%
11.2%
31.9%
34.1%
13.2%
50.6%
38.4%
37.9%
48.6%

74.6%
54.4%
37.9%
24.3%
32%
15.5%
11.7%
36.9%
34.9%
17.6%
55.3%
54.4%
37.9%
44%

78%
61.9%
37.1%
48.7%
38.6%
10.7%
10.2%
41.6%
35.5%
14.2%
51.3%
34%
35.5%
52.3%

17.9%

13.6%

21.8%

32.8%
49.8%

26.2%
48.5%

21.2%
57.4%

44.4%

49.5%

57.9%

21.5%

29.1%

33.5%

In the sample as a whole, TSH levels were correlated with
heart rate (𝑟 = .124, 𝑃 < .05), systolic blood pressure (𝑟 =
.164, 𝑃 < .01), diastolic blood pressure (𝑟 = .22, 𝑃 < .001),
and BMI (𝑟 = .15, 𝑃 < .02). The scores on hyper- versus
hypothyroid subscales were not significantly correlated with
TSH levels.

5. Discussion
Many postpartum women feel exhausted, depressed, and
not able to concentrate. Even physical symptoms such as
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Table 4: Comparisons of frequencies of “severe or vey severe” symptom reports on thyroid symptom checklist by group.
Symptom
Lack of energy
Irritability
Nervousness
Weight loss
Sweating
Shaking hands
Palpitations
Heat Intolerance
Dry hair
Puffy face
Dry skin
Hair falling out
Constipation
Aches and pains
Tingling or numbness
Cold intolerance
Poor memory
Lack of concentration
Depression
∗∗

TPO negative (a)

TPO positive
PPT negative
(b)

PPT positive (c)

13.2%
9.5%
5%
3.9%
4.4%
1.8%
0.08%
5.5%
5.1%
0.08%
11.9%
13.5%
7.1%
10.4%
3%
3.3%
6.4%
6.0%
3.3%

18%
5.9%
5.2%
5.9%
5.9%
1.5%
0%
8.2%
10.4%
0.08%
9.7%
14.1%
12.7%
11.1%
4.4%
2.2%
10.4%
4.4%
8.3%

18% (∗∗ a, c)
11.4%
8.6%
8.0%
9.2%
6.1% (∗∗ b, c)
1.2%
8.6% (∗∗ a, c)
12.3%
0.06%
12.8%
14.7%
13.5%
11.7%
2.5%
6.7% (∗∗ b, c)
13.5% (∗∗ a, c)
12.8% (∗∗ b, c)
6.1%

indicate 𝑃 < 0.003.

hair falling out were reported as occurring by a third of
postpartum women who were TPO negative in the study.
Certainly postpartum women are often dealing with many
demands and stressors [12–14]. Differentiating the “normal”
postpartum experience from the experience of women with
thyroid disease cannot rely on symptom reports. However,
severity of symptoms was clearly different for both groups of
TPO positive women. The TPO positive women who did not
develop thyroiditis were different in hypo- and hyperthyroid
subscale scores compared to TPO negative women. They also
had significant differences in particular symptom severities.
The presence of measurable thyroid autoantibodies, whether
or not PPT develops, indicates an autoimmune perturbation
in the gland even in euthyroid women. We and others have
reported that the presence of TPO autoantibodies alone may
be associated with postpartum depression [15, 16]. Thyroid
inflammation could have subtle effects on neurological function.
When PPT does develop, it is unlike other autoimmune
diseases in that it is reversible, although many women who
develop PPT go on to later chronic hypothyroidism. It is also
an unusual disease in that as yet unknown postpartum physiological changes unmask the disease in susceptible women.
The observation that perceived stress was significantly higher
in the PPT group is noteworthy. The distress associated with
the disease is likely additive with the usual stressors associated
with the postpartum.
This study should raise the awareness of providers to
the need to screen for TPO autoantibodies, since these
women appear to be experiencing more postpartum distress

and are at risk for development of PPT. Screening for TPO
autoantibodies is currently not a clinical recommendation
for all pregnant women and therefore many cases of PPT are
missed. In our study, of the 26 who were identified with PPT,
only two would have returned to their health care provider
based on their perceptions of the severity of their symptoms.
Even with referrals being made for all the PPT positive
women in the study, only two were actually treated. Treatment
could have included thyroid hormone replacement, antidepressants, and supportive care, but the usual approach was to
watch and wait. The return to euthyroidism after PPT does
not necessarily herald a healthy thyroid gland, as the risk for
permanent thyroid disease as well as recurrence of PPT in
subsequent pregnancies is very significant [17]. In addition,
the quality of life for women with PPT as well as those who
are TPO positive is likely to be impaired by severity of some
of the symptoms we measured as well as by general perceived
stress. Clearly there is a need for health care providers to
be more aware of this condition, as it may appear after the
usual 6-week postpartum visit and then may be present in the
primary care setting.

6. Limitations
There are several important limitations to this study. The
number of participants with PPT was small. The thyroid
symptom list may have inadequately captured the symptoms
of PPT, and the symptom and stress data were self-report.
The designation of PPT status was based on a change from
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normal range TSH levels to out of range levels, without a full
thyroid panel and clinical diagnosis. Women who became
PPT positive were so informed and thus this may have
influenced their responses in subsequent home visits.
Additional studies are needed to determine the most
appropriate symptom screenings useful in diagnosing PPT.
However, these data should prompt clinicians to investigate thyroid function when women report severe exhaustion, sleep disturbances, weight gain, and hair loss in the
postpartum period. Attributing these symptoms to normal
postpartum occurrences can cause unnecessary suffering for
some new mothers.
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